Search

Your search keyword '"Chan, Guanhao"' showing total 8 results
Start Over Author "Chan, Guanhao"
8 results on '"Chan, Guanhao"'

1. Global Impact of 10- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in All Ages: The PSERENADE Project

Author

Bennett, Julia C., primary, Knoll, Maria D., additional, Kagucia, Eunice W., additional, Garcia Quesada, Maria, additional, Zeger, Scott L, additional, Hetrich, Marissa K., additional, Yang, Yangyupei, additional, Herbert, Carly B., additional, Ogyu, Anju, additional, Cohen, Adam L., additional, Yildirim, Inci, additional, Winje, Brita A., additional, Von Gottberg, Ann, additional, Viriot, Delphine, additional, van der Linden, Mark, additional, Valentiner-Branth, Palle, additional, Suga, Shigeru, additional, Steens, Anneke, additional, Skoczyńska, Anna, additional, Sinkovec Zorko, Nadja, additional, Scott, J. Anthony G., additional, Savulescu, Camelia, additional, Savrasova, Larisa, additional, Sanz, Juan Carlos, additional, Russell, Fiona M., additional, Ricketson, Leah J., additional, Puentes, Rodrigo, additional, Nuorti, J. Pekka, additional, Mereckiene, Jolita, additional, McMahon, Kimberley, additional, McGeer, Allison, additional, Mad'arová, Lucia, additional, Mackenzie, Grant, additional, MacDonald, Laura, additional, Lepp, Tiia, additional, Ladhani, Shamez, additional, Kristinsson, Karl G., additional, Kozakova, Jana, additional, Klein, Nicola P., additional, Jayasinghe, Sanjay, additional, Ho, Pak-Leung, additional, Hilty, Markus, additional, Heyderman, Robert S., additional, Hasanuzzaman, Md., additional, Hammitt, Laura L., additional, Guevara, Marcela, additional, Grgic-Vitek, Marta, additional, Gierke, Ryan, additional, Georgakopoulou, Theano, additional, Galloway, Yvonne M., additional, Diawara, Idrissa, additional, Desmet, Stefanie, additional, De Wals, Philippe, additional, Dagan, Ron, additional, Colzani, Edoardo, additional, Cohen, Cheryl, additional, Ciruela, Pilar, additional, Chuluunbat, Urtnasan, additional, Chan, Guanhao, additional, Camilli, Romina, additional, Bruce, Michael G., additional, Brandileone, Maria-Cristina C., additional, Bigogo, Godfrey M., additional, Ampofo, Krow, additional, Feikin, Daniel R., additional, Hayford, Kyla, additional, and PSERENADE Team, The, additional

Published
2024
Full Text
View/download PDF

2. Imported Monkeypox, Singapore

Author

Yong, Sarah Ee Fang, Ng, Oon Tek, Ho, Zheng Jie Marc, Mak, Tze Minn, Marimuthu, Kalisvar, Vasoo, Shawn, Yeo, Tsin Wen, Ng, Yi Kai, Cui, Lin, Ferdous, Zannatul, Chia, Po Ying, Aw, Bryan Jun Wei, Manauis, Charmaine Malenab, Low, Constance Khia Ki, Chan, Guanhao, Peh, Xinyi, Lim, Poh Lian, Chow, Li Ping Angela, Chan, Monica, Lee, Vernon Jian Ming, Lin, Raymond Tzer Pin, Heng, Mok Kwee Derrick, and Leo, Yee Sin

Subjects
Human monkeypox, Vaccination, Quarantine, Zoonoses, Travelers, Disease susceptibility, Smallpox vaccine -- International trade, Health
Abstract

Monkeypox is a zoonosis endemic to West and Central Africa; human cases were first reported in 1970 (1). An outbreak ongoing in Nigeria since 2017 is the largest documented (2). [...]

Published
2020
Full Text
View/download PDF

3. Changes in Invasive Pneumococcal Disease Caused by Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project

Author

Bennett, Julia C, Hetrich, Marissa K, Quesada, Maria Garcia, Sinkevitch, Jenna N, Knoll, Maria Deloria, Feikin, Daniel R, Zeger, Scott L, Kagucia, Eunice W, Cohen, Adam L, Ampofo, Krow, Brandileone, Maria-Cristina C, Bruden, Dana, Camilli, Romina, Castilla, Jesús, Chan, Guanhao, Cook, Heather, Cornick, Jennifer E, Dagan, Ron, Dalby, Tine, Danis, Kostas, Miguel, Sara de, Wals, Philippe De, Desmet, Stefanie, Georgakopoulou, Theano, Gilkison, Charlotte, Grgic-Vitek, Marta, Hammitt, Laura L, Hilty, Markus, Ho, Pak-Leung, Jayasinghe, Sanjay, Kellner, James D, Kleynhans, Jackie, Knol, Mirjam J, Kozakova, Jana, Kristinsson, Karl G, Ladhani, Shamez N, MacDonald, Laura, Mackenzie, Grant A, Mad'arová, Lucia, McGeer, Allison, Mereckiene, Jolita, Morfeldt, Eva, Mungun, Tuya, Muñoz-Almagro, Carmen, Nuorti, J Pekka, Paragi, Metka, Pilishvili, Tamara, Puentes, Rodrigo, Saha, Samir K, Khan, Aalisha Sahu, Savrasova, Larisa, Scott, J Anthony, Skoczyńska, Anna, Suga, Shigeru, Linden, Mark van der, Verani, Jennifer R, Gottberg, Anne von, Winje, Brita A, Yildirim, Inci, Zerouali, Khalid, Hayford, Kyla, and The Pserenade Team

Subjects
serotypes, pneumococcal conjugate vaccines, vaccine impact, invasive pneumococcal disease
Abstract

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for

Published
2021

4. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures

Author

Pung, Rachael, primary, Chiew, Calvin J, additional, Young, Barnaby E, additional, Chin, Sarah, additional, Chen, Mark I-C, additional, Clapham, Hannah E, additional, Cook, Alex R, additional, Maurer-Stroh, Sebastian, additional, Toh, Matthias P H S, additional, Poh, Cuiqin, additional, Low, Mabel, additional, Lum, Joshua, additional, Koh, Valerie T J, additional, Mak, Tze M, additional, Cui, Lin, additional, Lin, Raymond V T P, additional, Heng, Derrick, additional, Leo, Yee-Sin, additional, Lye, David C, additional, Lee, Vernon J M, additional, Kam, Kai-qian, additional, Kalimuddin, Shirin, additional, Tan, Seow Yen, additional, Loh, Jiashen, additional, Thoon, Koh Cheng, additional, Vasoo, Shawn, additional, Khong, Wei Xin, additional, Suhaimi, Nur-Afidah, additional, Chan, Sherlynn JH, additional, Zhang, Emma, additional, Oh, Olivia, additional, Ty, Albert, additional, Tow, Charlene, additional, Chua, Yi Xian, additional, Chaw, Wei Liang, additional, Ng, Yixiang, additional, Abdul-Rahman, Farid, additional, Sahib, Shafiq, additional, Zhao, Zheng, additional, Tang, Cheryl, additional, Low, Constance, additional, Goh, Ee Hui, additional, Lim, Georgina, additional, Hou, Yan'an, additional, Roshan, Imran, additional, Tan, James, additional, Foo, Kelly, additional, Nandar, Khine, additional, Kurupatham, Lalitha, additional, Chan, Pei Pei, additional, Raj, Pream, additional, Lin, Yijun, additional, Said, Zubaidah, additional, Lee, Anne, additional, See, Cherie, additional, Markose, Jessey, additional, Tan, Joanna, additional, Chan, Guanhao, additional, See, Wanhan, additional, Peh, Xinyi, additional, Cai, Vincent, additional, Chen, Wen Kai, additional, Li, Zongbin, additional, Soo, Roy, additional, Chow, Angela LP, additional, Wei, Wycliffe, additional, Farwin, Aysha, additional, and Ang, Li Wei, additional

Published
2020
Full Text
View/download PDF

5. A case of imported Monkeypox in Singapore

Author

Ng, Oon Tek, primary, Lee, Vernon, additional, Marimuthu, Kalisvar, additional, Vasoo, Shawn, additional, Chan, Guanhao, additional, Lin, Raymond Tzer Pin, additional, and Leo, Yee Sin, additional

Published
2019
Full Text
View/download PDF

6. Measles Ring Vaccination in Dormitories: An Outbreak Containment Measure and Simulation Study

Author

Pung, Rachael, primary, Lee, Tau Hong, additional, Peh, Xinyi, additional, Cui, Lin, additional, poh, Cuiqin, additional, Low, Constance, additional, Chen, Mark I-Cheng, additional, Farwin, Aysha, additional, Chan, Guanhao, additional, Hou, Yan'an, additional, Ng, Yi Kai, additional, Cook, Alex R, additional, Soon, Margaret, additional, Chan, Monica, additional, Sadarangani, Sapna P., additional, Barkham, Timothy, additional, Lye, David Chien, additional, Lin, Raymond Tzer Pin, additional, Vasoo, Shawn, additional, Leo, Yee-Sin, additional, and Lee, Vernon J., additional

Published
2019
Full Text
View/download PDF

7. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.

Author

Deloria Knoll, Maria, Bennett, Julia C., Garcia Quesada, Maria, Kagucia, Eunice W., Peterson, Meagan E., Feikin, Daniel R., Cohen, Adam L., Hetrich, Marissa K., Yang, Yangyupei, Sinkevitch, Jenna N., Ampofo, Krow, Aukes, Laurie, Bacci, Sabrina, Bigogo, Godfrey, Brandileone, Maria-Cristina C., Bruce, Michael G., Camilli, Romina, Castilla, Jesús, Chan, Guanhao, and Chanto Chacón, Grettel

Subjects
LOW-income countries, CONSUMER preferences, PNEUMOCOCCAL vaccines, ADULTS
Abstract

Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project.

Author

Bennett, Julia C., Hetrich, Marissa K., Garcia Quesada, Maria, Sinkevitch, Jenna N., Deloria Knoll, Maria, Feikin, Daniel R., Zeger, Scott L., Kagucia, Eunice W., Cohen, Adam L., Ampofo, Krow, Brandileone, Maria-Cristina C., Bruden, Dana, Camilli, Romina, Castilla, Jesús, Chan, Guanhao, Cook, Heather, Cornick, Jennifer E., Dagan, Ron, Dalby, Tine, and Danis, Kostas

Subjects
STREPTOCOCCUS pneumoniae, PNEUMOCOCCAL vaccines, POISSON regression, INFANTS
Abstract

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3 + 0 schedule constrains generalizability and data from these settings are needed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results